Document Detail


Prostate cancer mortality in relation to screening by prostate-specific antigen testing and digital rectal examination: a population-based study in middle-aged men.
MedLine Citation:
PMID:  17641982     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Although prostate cancer screening by measurement of serum prostate-specific antigen (PSA) and digital rectal examination (DRE) is common in clinical practice, the impact of such screening on prostate cancer-specific mortality remains uncertain. METHODS: Data from a population-based case-control study in King County, Washington, among men aged 50-64 years (706 cases, 645 controls) were used to examine the relationships between PSA and DRE screening and fatal prostate cancer and other-cause mortality. Incident cases were diagnosed in 1993-1996, identified via the Seattle-Puget Sound SEER cancer registry and followed for vital status through 1 June 2007. Controls were ascertained by random digit dialing and frequency age-matched to cases. The screening variable used in this analysis was self-reported receipt of one or more PSA and/or DRE tests performed as part of a routine checkup in the five-year period before diagnosis or reference date. RESULTS: A smaller proportion of men with fatal prostate cancer had one or more PSA and/or DRE screening tests compared to controls, resulting in an adjusted odds ratios (OR) of 0.38 (95% CI 0.19-0.77). There was no association, however, between PSA and/or DRE screening and other-cause mortality (OR = 1.02; 95% CI 0.51-2.02). CONCLUSIONS: Results of this study suggest a reduction in prostate cancer-specific mortality associated with PSA and/or DRE screening in middle-aged men. Findings should be interpreted cautiously, however, as results are based on observational data. Further, the study was not able to separate the relative efficacy of PSA versus DRE screening.
Authors:
Ilir Agalliu; Noel S Weiss; Daniel W Lin; Janet L Stanford
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural     Date:  2007-07-20
Journal Detail:
Title:  Cancer causes & control : CCC     Volume:  18     ISSN:  0957-5243     ISO Abbreviation:  Cancer Causes Control     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-08-09     Completed Date:  2007-12-07     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9100846     Medline TA:  Cancer Causes Control     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  931-7     Citation Subset:  IM    
Affiliation:
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N, M4-B874, Seattle, WA 98109, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Case-Control Studies
Confidence Intervals
Humans
Interviews as Topic
Male
Mass Screening / methods*
Middle Aged
Neoplasm Staging
Odds Ratio
Palpation / methods*
Prostate-Specific Antigen*
Prostatic Neoplasms / blood,  diagnosis*,  mortality*,  pathology
Rectum
Retrospective Studies
Survival Analysis
Grant Support
ID/Acronym/Agency:
N01-CN-05230/CN/NCI NIH HHS; P50-CA97186/CA/NCI NIH HHS; R01-CA56678/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
EC 3.4.21.77/Prostate-Specific Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Sun exposure concern, sun protection behaviors and physical activity among Australian adults.
Next Document:  Onychomycosis by Scytalidium dimidiatum in green tea leaf pluckers: report of two cases.